Literature DB >> 31141817

Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior.

Joshua D Gross1,2,3, Shane W Kaski1,2,3, Karl T Schmidt4, Elizabeth S Cogan4, Kristen M Boyt4, Kim Wix1, Adam B Schroer1, Zoe A McElligott4, David P Siderovski5,6, Vincent Setola1,2,3.   

Abstract

Kappa opioid receptor (KOR) agonists show promise in ameliorating disorders, such as addiction and chronic pain, but are limited by dysphoric and aversive side effects. Clinically beneficial effects of KOR agonists (e.g., analgesia) are predominantly mediated by heterotrimeric G protein signaling, whereas β-arrestin signaling is considered central to their detrimental side effects (e.g., dysphoria/aversion). Here we show that Regulator of G protein Signaling-12 (RGS12), via independent signaling mechanisms, simultaneously attenuates G protein signaling and augments β-arrestin signaling downstream of KOR, exhibiting considerable selectivity in its actions for KOR over other opioid receptors. We previously reported that RGS12-null mice exhibit increased dopamine transporter-mediated dopamine (DA) uptake in the ventral (vSTR), but not dorsal striatum (dSTR), as well as reduced psychostimulant-induced hyperlocomotion; in the current study, we found that these phenotypes are reversed following KOR antagonism. Fast-scan cyclic voltammetry studies of dopamine (DA) release and reuptake suggest that striatal disruptions to KOR-dependent DAergic neurotransmission in RGS12-null mice are restricted to the nucleus accumbens. In both ventral striatal tissue and transfected cells, RGS12 and KOR are seen to interact within a protein complex. Ventral striatal-specific increases in KOR levels and KOR-induced G protein activation are seen in RGS12-null mice, as well as enhanced sensitivity to KOR agonist-induced hypolocomotion and analgesia-G protein signaling-dependent behaviors; a ventral striatal-specific increase in KOR levels was also observed in β-arrestin-2-deficient mice, highlighting the importance of β-arrestin signaling to establishing steady-state KOR levels in this particular brain region. Conversely, RGS12-null mice exhibited attenuated KOR-induced conditioned place aversion (considered a β-arrestin signaling-dependent behavior), consistent with the augmented KOR-mediated β-arrestin signaling seen upon RGS12 over-expression. Collectively, our findings highlight a role for RGS12 as a novel, differential regulator of both G protein-dependent and -independent signaling downstream of KOR activation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31141817      PMCID: PMC6785087          DOI: 10.1038/s41386-019-0423-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  91 in total

1.  U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking.

Authors:  S Schenk; B Partridge; T S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  1999-06       Impact factor: 4.530

2.  The therapeutic potential of κ-opioids for treatment of pain and addiction.

Authors:  Charles Chavkin
Journal:  Neuropsychopharmacology       Date:  2011-01       Impact factor: 7.853

3.  Community Approaches to the Opioid Crisis.

Authors:  Howard Koh
Journal:  JAMA       Date:  2015-10-13       Impact factor: 56.272

Review 4.  Dynorphin, Dysphoria, and Dependence: the Stress of Addiction.

Authors:  Charles Chavkin; George F Koob
Journal:  Neuropsychopharmacology       Date:  2016-01       Impact factor: 7.853

Review 5.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction.

Authors:  Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander
Journal:  Annu Rev Public Health       Date:  2015-01-12       Impact factor: 21.981

Review 6.  Role of kappa-opioid receptors in stress and anxiety-related behavior.

Authors:  Ashlee Van't Veer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

Review 7.  Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment.

Authors:  Nicole A Crowley; Thomas L Kash
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-01-12       Impact factor: 5.067

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake.

Authors:  Abigail G Schindler; Daniel I Messinger; Jeffrey S Smith; Haripriya Shankar; Richard M Gustin; Selena S Schattauer; Julia C Lemos; Nicholas W Chavkin; Catherine E Hagan; John F Neumaier; Charles Chavkin
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

10.  Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release.

Authors:  Elena H Chartoff; Shayla R Ebner; Angela Sparrow; David Potter; Phillip M Baker; Michael E Ragozzino; Mitchell F Roitman
Journal:  Neuropsychopharmacology       Date:  2015-08-04       Impact factor: 7.853

View more
  8 in total

1.  mTORC1 pathway is involved in the kappa opioid receptor activation-induced increase in excessive alcohol drinking in mice.

Authors:  Yan Zhou; Yupu Liang; Mary Jeanne Kreek
Journal:  Pharmacol Biochem Behav       Date:  2020-05-26       Impact factor: 3.533

2.  Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.

Authors:  C Austin Zamarripa; Jennifer E Naylor; Sally L Huskinson; E Andrew Townsend; Thomas E Prisinzano; Kevin B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2020-01-31       Impact factor: 4.530

3.  The stability of tastant detection by mouse lingual chemosensory tissue requires Regulator of G protein Signaling-21 (RGS21).

Authors:  Adam B Schroer; Kayla W Branyan; Joshua D Gross; Paul D Chantler; Adam J Kimple; Aurelie Vandenbeuch; David P Siderovski
Journal:  Chem Senses       Date:  2021-01-01       Impact factor: 3.160

Review 4.  Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.

Authors:  Shane W Kaski; Allison N White; Joshua D Gross; David P Siderovski
Journal:  Anesth Analg       Date:  2021-02-01       Impact factor: 6.627

Review 5.  Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management.

Authors:  Nicolas B Senese; Ram Kandasamy; Kelsey E Kochan; John R Traynor
Journal:  Front Mol Neurosci       Date:  2020-01-24       Impact factor: 5.639

6.  Macrophage regulator of G-protein signaling 12 contributes to inflammatory pain hypersensitivity.

Authors:  Gongsheng Yuan; Shuting Yang; Mayank Gautam; Wenqin Luo; Shuying Yang
Journal:  Ann Transl Med       Date:  2021-03

7.  Involvement of GRK2 in modulating nalfurafine-induced reduction of excessive alcohol drinking in mice.

Authors:  Yan Zhou; Yupu Liang
Journal:  Neurosci Lett       Date:  2021-06-29       Impact factor: 3.197

8.  Short stature and combined immunodeficiency associated with mutations in RGS10.

Authors:  Ivan K Chinn; Zhihui Xie; Eunice C Chan; Bianca M Nagata; Alexey Koval; Wei-Sheng Chen; Fan Zhang; Sundar Ganesan; Diana N Hong; Motoshi Suzuki; Glenn Nardone; Ian N Moore; Vladimir L Katanaev; Andrea E Balazs; Chengyu Liu; James R Lupski; Jordan S Orange; Kirk M Druey
Journal:  Sci Signal       Date:  2021-07-27       Impact factor: 9.517

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.